OraSure Technologies reported second quarter 2026 financial results, posting total net revenues of $30.6 million, a 2% decrease year-over-year but up 9.7% sequentially. The company achieved GAAP operating income of $5.4 million and net income of $6.2 million, driven by a $22.6 million reduction in contingent consideration liability related to the CT/NG test submission plan update. Core revenues remained flat at $30.6 million year-over-year, with Diagnostics up 1% to $19.4 million. The company repurchased approximately $2 million of common stock during the quarter and holds $161 million in cash. OraSure Technologies operates in the medical diagnostics industry, developing and distributing rapid diagnostic tests and sample collection devices.

On June 11, 2026, OraSure Technologies, Inc. announced that the U.S. Food and Drug Administration (FDA) cleared the Colli-Pee Dx Urine Collection Kit from its subsidiary DNA Genotek Inc. The kit is designed for use with Roche Molecular Systems, Inc. tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium on Roche's cobas 5800, 6800, and 8800 molecular diagnostic systems. The FDA-cleared kit enables at-home self-collection of first-void urine for both male and female patients. OraSure Technologies is a medical diagnostics company that develops and rapid diagnostic tests.